Arcturus Therapeutics Holdings Inc. ARCT
13.85
(0.27)
(1.91%)
as of 25 Sep
- Market cap
- $412.4M
- P/E
- 0.0×
Follow ARCT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (46.31%) | (37.01%) | (28.92%) | (27.43%) |
+8 more TTM periods Free account |
|
| (34.96%) | (27.26%) | (21.39%) | (20.43%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(55.20%) | (41.72%) | (31.06%) | (29.66%) | |
Average Days of Receivables |
22.53 | 8.96 | 24.76 | 29.73 | |
Free Cash Flow per Share |
(2.56) | (2.06) | (2.72) | (2.16) | |
Free Cash Flow |
(72.77) | (58.63) | (74.50) | (58.65) | |
Capital Expenditures |
(0.04) | (0.06) | (0.23) | (0.32) | |
Piotroski F-Score |
1.00 | 3.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(20.02%) | (14.54%) | (16.69%) | (12.68%) | |
Accounts Receivable Turnover |
3.09 | 6.88 | 17.20 | 5.12 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
295.50% | 180.67% | 136.79% | 134.75% | |
Selling, General and Administrative Expense of Revenue |
152.82% | 80.84% | 56.17% | 45.52% | |
Share Based Compensation of Revenue |
71.85% | 42.17% | 30.97% | 28.25% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.74 | 1.13 | 0.87 | |
Depreciation/Fixed assets |
0.51 | 0.47 | 0.45 | 0.43 | |
Capex/Depreciation |
(0.01) | (0.02) | (0.08) | (0.10) | |
Revenue per Share |
1.03 | 1.93 | 3.00 | 3.59 | |
Operating CF per Share |
(2.56) | (2.06) | (2.71) | (2.15) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(317.61%) | (143.80%) | (80.19%) | (68.35%) |
Columns are period end dates